144 related articles for article (PubMed ID: 35180771)
1. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
Sato J; Shimizu T; Koyama T; Iwasa S; Shimomura A; Kondo S; Kitano S; Yonemori K; Fujiwara Y; Tamura K; Suzuki T; Takase T; Nagai R; Yamaguchi K; Semba T; Zhao ZM; Ren M; Yamamoto N
Clin Cancer Res; 2022 May; 28(9):1783-1791. PubMed ID: 35180771
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.
Ida H; Shimizu T; Nishino M; Nakamura Y; Yazaki S; Katsuya Y; Sato J; Koyama T; Iwasa S; Sudo K; Kondo S; Yonemori K; Shitara K; Shiono S; Matsuoka D; Yasuda K; Otake Y; Suzuki T; Takase T; Takashima S; Yamaguchi K; Semba T; Yamamoto N
Cancer Res Commun; 2023 Jul; 3(7):1189-1199. PubMed ID: 37435605
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.
Nishio M; Murakami S; Kawakami H; Okishio K; Tamiya M; Kobayashi H; Fujimoto D; Sugawara S; Kozuki T; Oya Y; Izumi H; Shiroyama T; Satouchi M; Yamamoto N; Kaname S; Matsuoka D; Otake Y; Takase T; Semba T; Azuma K
Cancer Res Commun; 2024 Jan; 4(1):226-235. PubMed ID: 38181055
[TBL] [Abstract][Full Text] [Related]
4. First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.
Doi T; Matsubara N; Naito Y; Kuboki Y; Harano K; Ono M; Urasaki T; Ohmoto A; Kawanai T; Hisai T; Ikezawa H; Shiba S; Ito K; Semba T; Asano O; Takahashi S
Cancer; 2023 Aug; 129(15):2348-2359. PubMed ID: 37080942
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort.
Shitara K; Hirao M; Iwasa S; Oshima T; Komatsu Y; Kawazoe A; Sato Y; Hamakawa T; Yonemori K; Machida N; Yuki S; Suzuki T; Okumura S; Takase T; Semba T; Zimmermann B; Teng A; Yamaguchi K
Clin Cancer Res; 2023 Apr; 29(8):1460-1467. PubMed ID: 36730323
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
Masuda N; Ono M; Mukohara T; Yasojima H; Shimoi T; Kobayashi K; Harano K; Mizutani M; Tanioka M; Takahashi S; Kogawa T; Suzuki T; Okumura S; Takase T; Nagai R; Semba T; Zhao ZM; Ren M; Yonemori K
Eur J Cancer; 2022 Jun; 168():108-118. PubMed ID: 35500404
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
Kawazoe A; Yamamoto N; Sugimoto N; Kawakami H; Oshima T; Yamaguchi K; Hino K; Hirao M; Kurokawa Y; Kawakami T; Tsuda M; Hara H; Kaname S; Matsuoka D; Otake Y; Yasuda K; Takase T; Takashima S; Semba T; Muro K
Clin Cancer Res; 2024 Apr; 30(7):1264-1272. PubMed ID: 38295160
[TBL] [Abstract][Full Text] [Related]
8. Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.
Tabernero J; Bedard PL; Bang YJ; Vieito M; Ryu MH; Fagniez N; Chadjaa M; Soufflet C; Masson N; Gazzah A
Cancer Res Commun; 2023 Aug; 3(8):1662-1671. PubMed ID: 37645622
[TBL] [Abstract][Full Text] [Related]
9. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
Evans TRJ; Dean E; Molife LR; Lopez J; Ranson M; El-Khouly F; Zubairi I; Savulsky C; Reyderman L; Jia Y; Sweeting L; Greystoke A; Barriuso J; Kristeleit R
Br J Cancer; 2019 Feb; 120(4):379-386. PubMed ID: 30679780
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
[TBL] [Abstract][Full Text] [Related]
12. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
[TBL] [Abstract][Full Text] [Related]
13. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
Chiorean EG; Hurwitz HI; Cohen RB; Schwartz JD; Dalal RP; Fox FE; Gao L; Sweeney CJ
Ann Oncol; 2015 Jun; 26(6):1230-1237. PubMed ID: 25787923
[TBL] [Abstract][Full Text] [Related]
16. Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer.
Udagawa H; Takahashi S; Hirao M; Tahara M; Iwasa S; Sato Y; Hamakawa T; Shitara K; Horinouchi H; Chin K; Masuda N; Suzuki T; Okumura S; Takase T; Nagai R; Yonemori K
Cancer Med; 2023 Jan; 12(2):1269-1278. PubMed ID: 35864593
[TBL] [Abstract][Full Text] [Related]
17. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
Wang L; Luo Y; Ren S; Zhang Z; Xiong A; Su C; Zhou J; Yu X; Hu Y; Zhang X; Dong X; Meng S; Wu F; Hou X; Dai Y; Song W; Li B; Wang ZM; Xia Y; Zhou C
J Thorac Oncol; 2024 Mar; 19(3):465-475. PubMed ID: 37879536
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
